Drug Search Results
More Filters [+]

JointStem

Alternative Names: JointStem
Latest Update: 2024-05-15
Latest Update Note: PubMed Publication

Product Description

autologous adipose tissue derived mesenchymal stem cells (AdMSC) (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02674399)

Mechanisms of Action: Stem Cell Therapy

Novel Mechanism: Yes

Modality: Cell Therapy

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: R-Bio
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for JointStem

Countries in Clinic: Korea, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Osteoarthritis, Knee

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

BSR-CTph3-JS1_FU

P3

Active, not recruiting

Osteoarthritis, Knee

2026-12-23

15%

JS-OAP3-US01

P3

Recruiting

Osteoarthritis, Knee

2024-06-30

15%

Recent News Events